Krystal Biotech KRYS
NASDAQ KRYS
$333.01 -2.05 (-0.61%)
As of: Sep 30, 2026 · 3:59 PM EDT

Krystal Biotech (KRYS) EV to CFO (2024 - 2026)

Updated

Krystal Biotech's EV to CFO came in at 37.29 for Q2 2026, up 121.2% from 16.86 a year earlier and up 37.6% from the prior quarter.

Analysis

Krystal Biotech (KRYS) EV to CFO (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Krystal Biotech reported EV to CFO of 28.54, up 273.8% year-over-year; for FY2025, it was 31.71, unchanged from FY2024.

  • Going back by year, EV to CFO was 31.71 in FY2024.
  • The Q2 2026 figure represents the highest quarterly EV to CFO since Q3 2024.
  • Year-over-year, EV to CFO increased in 1 of the last four quarters, with growth averaging 9.2%.
  • Business Quant data shows KRYS's EV to CFO at 27.09 (Q1 2026), 31.71 (Q4 2025) and 24.89 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Krystal Biotech 9.92 Bn 6.69 Bn 112.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 37.29
Mar 31, 2026 27.09
Dec 31, 2025 31.71
Sep 30, 2025 24.89
Jun 30, 2025 16.86
Mar 31, 2025 33.17
Dec 31, 2024 31.71
Sep 30, 2024 73.35
API Access

Krystal Biotech EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=KRYS&period=max&api_key=YOUR_API_KEY